Is Chemomab Therapeutics Ltd. (CMMB) a Buy, Sell, or Hold?
NASDAQ : CMMB
Chemomab Therapeutics Ltd.
$1.52 USD
$0 (0.0%)
- Volume
- 72.78K
- Average Volume
- 123.1K
- Market Capitalization
- $9.36M
- P/E Ratio
- -1.38
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $4.84
- Year Low
- $1.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.31
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Adi Mor George |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CMMB |
| CUSIP | 16385C203 |
| CIK | 0001534248 |
| Web | https://www.chemomab.com |
| Phone | 972 77 331 0156 |
| Currency | USD |
| Employees | 12 |
| Country | IL |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.31 |
| Quick Ratio | 10.31 |
| Cash Ratio | 5.31 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -1.41 |
| Price / Cash Flow | -0.83 |
| Price / Book | 1.13 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.42 |
| Trailing P/E Ratio | -1.38 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | -$9M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -67.85% |
| Return on Assets | -63.15% |
Financials Score
| AltmanZ Score | -9.57 |
| Piotroski Score | 1.00 |
| Working Capital | 10.36M |
| Total Assets | 11.81M |
| Ebit | -7.94M |
| Market Cap | 9.36M |
| Total Liabilities | 1.11M |
Poll Results
About Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Stock
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel. ...
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
2026-07-08 12:32:42
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
2026-07-08 07:35:00
Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medicine trial for the treatment of rheumatoid arthritis.
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 08:00:00
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update.
Frequently Asked Questions
-
What is the current Chemomab Therapeutics Ltd. (CMMB) stock price?
-
Chemomab Therapeutics Ltd.(NASDAQ:CMMB) stock price is $1.52 in the last trading session. During the trading session, CMMB stock reached the peak price of $4.84 while $1.35 was the lowest point it dropped to. The percentage change in CMMB stock occurred in the recent session was 0.0% while the dollar amount for the price change in CMMB stock was $0.
-
CMMB's industry and sector of operation?
-
The NASDAQ listed CMMB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CMMB?
-
John Lawler | Chief Development Officer
Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications
Adi Mor George | Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director
David Weiner | Interim Chief Medical Officer
Jack Lawler | Chief Development Officer -
How many employees does CMMB have?
-
Number of CMMB employees currently stands at 12. CMMB operates from Building 7, Tel Aviv, TA 6158002, IL.
-
Link for CMMB official website?
-
Official Website of CMMB is: https://www.chemomab.com
-
How do I contact CMMB?
-
CMMB could be contacted at phone #972 77 331 0156 and can also be accessed through its website. CMMB operates from Building 7, Tel Aviv, TA 6158002, IL.
-
How many shares of CMMB are traded daily?
-
The average number of CMMB shares traded daily for last 3 months was 123.1K.
-
What is the market cap of CMMB currently?
-
The market value of CMMB currently stands at $9.36M with its latest stock price at $1.52